Why Eli Lilly (LLY) rose 4.74%
Eli Lilly (LLY) rose 4.74% on August 5, 2026 — Eli Lilly beats, raises 2026 outlook on GLP-1 surge.
What happened
Eli Lilly beat consensus earnings, raised full-year 2026 revenue guidance, and reported surging Zepbound and Mounjaro sales across obesity and diabetes segments.
Why it moved
Higher revenue guidance on proven demand for GLP-1 obesity/diabetes drugs re-rates Lilly's near-term growth and justifies margin expansion; strong execution dispels prior caution about supply constraints and adoption…
Why it matters
A core driver of the GLP-1 / Obesity supercycle — Lilly's outsized beat and raised outlook validate the entire theme's durability after recent narrative weakness from Hims pressure and prior Lilly caution, reinforcing…
What would break the thesis
If Rx growth decelerates in coming quarters or supply constraints re-emerge and cap the raised outlook, the move will be reversed as a false signal.